Latest Insurance News

ImpediMed has secured A$15.2 million through a two-tranche placement and share purchase plan, alongside A$5 million in cost reductions, aiming for operating cashflow breakeven by H2 FY28.

Vanadium Resources raises about A$1 million through a placement to fund studies and site agreements for its Steelpoortdrift Vanadium Project and next-gen V-Iron Plant, aiming to supply Western critical mineral markets.

Viva Energy is progressing repairs at its Geelong Refinery following a fire that disrupted key units, aiming to resume near-full production by June while maintaining fuel supply.

ColCap Financial Limited (ASX:TT6) reported a 16% rise in net profit to $72.2 million for FY2025, driven by a 15% expansion in its loan portfolio to $19.3 billion and a series of record Residential Mortgage-Backed Securities issuances.

RocketBoots has secured a significant A$3.3 million activation contract with a tier-one multinational retailer and reported over 50% growth in its early sales pipeline, supported by a strong cash position of A$5 million.

Kore Potash made steady progress on its Kola Potash Project in Q1 2026, completing key marine and topographic studies while navigating design revisions and ongoing financing talks. The company’s formal sale process continues with one bidder remaining active and cash reserves at US$8.3 million.

hipages Group (ASX:HPG) has kicked off an on-market buy-back of up to 10% of its shares, signalling confidence in its undervalued stock amid strong cash flow and growth.

hipages Group has acquired a majority stake in VIZ Insurance, marking its strategic entry into the insurance sector for tradies and broadening its platform offerings.

Control Bionics progresses its scalable distributor-led model in North America, inks a strategic US partnership for iOS speech devices, and gains German reimbursement eligibility for NeuroNode, while managing cash flow amid NDIS delays.

ImpediMed reported a $3.5 million revenue in Q3 FY26, with reimbursement coverage in the US reaching 94.3%, supporting growth in heart health and weight management markets. New CEO Erik Anderson aims to accelerate commercial momentum and drive cash flow break-even.

Argent BioPharma secured a 48% stake in CannPal Animal Therapeutics, shipped its largest CannEpil® order to Ireland worth A$783,000, and filed a US provisional patent for its NanoBodies platform, underpinning its neuro-immune strategy and commercial growth.

Emyria Limited is extending its Empax mental health clinic network into New South Wales through a new partnership with Matilda Nepean Private Hospital, increasing treatment capacity and national reach ahead of a planned Q3 2026 launch.